Clinical trials: Disease or Disorder
Overweight or Obesity
Soy Peptide, Conjugated Linoleic Acid, Overweight or Obese, Body Composition
Soybean peptides are a mixture of active peptides obtained from the hydrolysis of soybean protein, which have biological activities such as antioxidant, blood pressure lowering, anti-fatigue and lipid lowering, etc.
- Trial name
- NCT04728399
- Testing
- Experimental group, Control group
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fangfang Zeng
Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
This study will examine the effect intravenously administered rigosertib has on the relationship between bone marrow blasts response and overall survival in myelodysplastic syndromes (MDS) patients who have 5-30% bone marrow…
- Conditions
- Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia, Cytopenia
- Trial name
- NCT01928537
- Testing
- rigosertib sodium
- Where
- 35 sites in United States, Australia and 6 more
- Volunteers
- 67 people
- Sponsor
- Traws Pharma, Inc.
Parkinson's Disease
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD: Group 1 Patients using Azilect and no other therapy.
- Trial name
- NCT00399477
- Testing
- rasagiline mesylate, Rasagiline mesylate plus Mirapex, Rasagiline mesylate with Levodopa
- Volunteers
- 200 people
- Sponsor
- Teva Neuroscience, Inc.
Refractory Hodgkin Lymphoma, Recurrent Adult Hodgkin's Lymphoma
INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma
A Phase 2, open-label study to evaluate the safety and efficacy of INCB040093 as monotherapy and as combination therapy with itacitinib (INCB039110) in subjects with relapsed or refractory Hodgkin Lymphoma.
- Trial name
- NCT02456675
- Testing
- INCB040093 Monotherapy, INCB040093, itacitinib
- Volunteers
- 8 people
- Sponsor
- Incyte Corporation
Cytomegalovirus Infections, Adenovirus Infection
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation
The purpose of this study is to evaluate whether virus-specific T cell lines (VSTs) are safe and can effectively control three viruses (EBV, CMV, and adenovirus) in patients who have had a stem cell transplant and also in…
- Conditions
- Cytomegalovirus Infections, Adenovirus Infection, EBV Infection
- Trial name
- ACES (NCT03475212)
- Testing
- Virus Specific T-cell (VST) infusion
- Where
- 30 sites in United States
- Volunteers
- 52 people
- Sponsor
- Pediatric Transplantation & Cellular Therapy Consortium
Acute HIV Infection
Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults
The purpose of this study is to assess the ability of the early initiation of cART or cART in combination with autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion to achieve a post-treatment control among…
- Trial name
- NCT02231281
- Testing
- cART(TDF/AZT+3TC+LPV/r), CTL infusion
- Where
- 7 sites in China
- Volunteers
- 65 people
- Sponsor
- Yongtao Sun, MD, PhD
Cervical Cancer, Recurrent
A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer
This is a Phase II clinical trial to evaluate the safety and efficacy of Utidelone, a genetically engineered epothilone derivative, combined with Toripalimab, a PD-1 inhibitor, in patients with recurrent or metastatic cervical…
- Conditions
- Cervical Cancer, Recurrent, Metastatic
- Trial name
- NCT07363330
- Testing
- Utidelone plus Toripalimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Zhongnan Hospital
Chronic Hepatitis B
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
Participants with chronic HBV infection will receive multiple doses of ARC-520 in combination with entecavir or tenofovir and be evaluated for safety and efficacy.
- Trial name
- NCT02452528
- Testing
- ARC-520, Entecavir, Tenofovir
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- Arrowhead Pharmaceuticals
Graft vs Host Disease
Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD
This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of universal T-cells engineered with chimeric…
- Trial name
- NCT06568328
- Testing
- Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Fujian Medical University
Weight Gain
Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults
The purpose of this research study is to test the safety and efficacy (how well it works) of exenatide as a treatment for weight gain associated with olanzapine in obese adults with Bipolar Disorder, Major Depressive Disorder…
- Trial name
- NCT00845507
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Cincinnati
Cryopyrin Associated Periodic Syndrome
The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
This study will assess the safety, tolerability and efficacy of canakinumab treatment in Canadian patient diagnosed with cryopyrin-associated periodic syndrome over a period of 18 months.
- Trial name
- NCT01105507
- Testing
- canakinumab (company code: ACZ885D)
- Where
- 2 sites in Canada
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myeloid, Chronic
Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy
This open-label, multicenter trial will evaluate the efficacy and safety of treatment with AMN107 in chronic myelogenous leukemia (CML) patients that are resistant and/or intolerant to imatinib mesylate therapy.
- Trial name
- NCT00264160
- Testing
- AMN107
- Where
- 4 sites in Israel
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Virus-HIV
Coronary Artery Disease (CAD) in Suppressed HIV-infected
HIV-infected patients with intermediate-high risk have a high prevalence of CAD and a substantial proportion of obstructive CAD.
- Trial name
- NCT02898896
- Testing
- blood test
- Where
- France
- Volunteers
- 62 people
- Sponsor
- University Hospital, Montpellier
Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Mindfulness Relaxation Compared With Relaxing Music and Standard Symptom Management Education in Treating Patients Who Are Undergoing Chemotherapy For Newly Diagnosed Solid Tumors
RATIONALE: Mindfulness relaxation, a technique to help patients quiet their thoughts and relax their bodies before and during chemotherapy, may reduce or prevent nausea and vomiting.
- Conditions
- Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific, Breast Cancer, Gastrointestinal Cancer
- Trial name
- NCT00086762
- Testing
- MR Therapy, Relaxing Music (RM) Therapy, Standard Symptom Management
- Where
- 9 sites in United States
- Volunteers
- 474 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroblastoma
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and…
- Trial name
- NCT03363373
- Testing
- GM-CSF + Naxitamab
- Where
- 20 sites in United States, Canada and 7 more
- Volunteers
- 122 people
- Sponsor
- Y-mAbs Therapeutics
Sepsis, Septic Shock
Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Patients.
Infections in critically ill patients are a major healthcare problem and an important source of morbidity and mortality. Since critically ill patients often have altered pharmacokinetics (PK) compared to non-critically ill…
- Conditions
- Sepsis, Septic Shock, Infection, Bacterial, Critically Ill
- Trial name
- PHARAOH (NCT04470973)
- Testing
- Cefuroxime, Amikacin
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Burns, Critical Illness
Indirect Calorimetry in Patients at Risk of Malnutrition
Burn patients treated in an outpatient clinic and ICU survivors are at risk of malnutrition. There are no clear guidelines determining the energy target in those two populations.
- Conditions
- Burns, Critical Illness, Indirect Calorimetry, Resting Energy Expenditure
- Trial name
- NCT04500483
- Testing
- indirect calorimetry
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- University of Liege
Alzheimer Disease
Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine
Current therapeutic approaches for the treatment of neurodegenerative diseases like Alzheimer disease (AD) offer limited and often transient symptomatic benefits to patients but do not mitigate the insidious loss of neuronal…
- Trial name
- NCT01696123
- Testing
- MLC601
- Where
- Iran
- Volunteers
- 125 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Relapsed or Refractory B Cell Non Hodgkin Lymphoma
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
The purpose of the study is to evaluate the safety、tolerability and preliminary efficacy of B019 in subjects with relapsed or refractory B-cell non-Hodgkin's lymphoma.
- Trial name
- NCT06970496
- Testing
- B019
- Where
- 7 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Acute Myocardial Infarction, Stable Angina
Development and Efficacy Evaluation of Integrated Chronic Care and Health Promotion Model for Patients With Coronary Artery Disease in Taiwan
The hypothesis of this project is to examine whether the integrated health care program as the intervention group can reduce the recurrence and mortality of coronary artery-related diseases than the traditional one as the…
- Trial name
- NCT01357096
- Testing
- Integrated health care team, Traditional group
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.